Spherix Media
Across the pharma lifecycle, an accurate and complete market view is essential to stay ahead of the curve and uncover emerging healthcare trends.
Inclusion body myositis and ASyS identified as most underserved IIM subtypes amid widespread calls for faster, safer, steroid-sparing therapies. EXTON, PA, August 7, 2025 – Despite recent increased use of intravenous immunoglobulin (IVIg) and biologics, the majority of patients with idiopathic inflammatory myopathies (IIM)—including classic dermatomyositis (DM), polymyositis (PM), and
Strong efficacy and safety perceptions, as well as favorable administration fuel utilization of the IL-23 class in Crohn’s disease, according to Spherix Global Insights. Exton, PA, August 6, 2025 – The Crohn’s disease (CD) treatment landscape is undergoing a radical transformation as newer mechanisms of action (MOAs), particularly IL-23 inhibitors
Physician perspectives point to strong interest in metabolic modulation as a novel pathway in sickle cell disease, particularly for patients who cannot currently access gene therapy for clinical or logistical reasons, according to Spherix Global Insights. EXTON, PA, August 6, 2025 — According to the latest findings from Spherix Global Insights’
Hematologists are poised to jump on new market entrants once available, as high unmet need and frustration with current treatment standards persist in w-AIHA. EXTON, PA, July 29, 2025— According to new findings from Spherix Global Insights’ syndicated Market Dynamix™ service, hematologists managing patients with warm autoimmune hemolytic anemia (w-AIHA)
Doctors, patients struggle with new drug coverage. The recent approval of a new drug to treat psoriatic arthritis (PsA) was a welcome development for people living with this painful condition and the doctors who treat them. But those enthusiastic to try Bimzelx (bimekizumab) have run into a common problem associated
Rheumatologists expect new mechanisms of action to reshape the SLE landscape as demand grows for safer, more effective options—particularly therapies with steroid-sparing potential and easier administration EXTON, PA, July 23, 2025 — Biologic use in systemic lupus erythematosus (SLE) is steadily rising, with U.S. rheumatologists now treating close to 40%
Despite new market entrants in the form of Gilead’s Livdelzi and Ipsen’s Iqirvo, US gastroenterologists report nearly half of PBC patients suffer from moderate to severe pruritus, underscoring an existing unmet need. Exton, PA, July 17, 2025 – The treatment landscape for primary biliary cholangitis (PBC) has undergone a marked
Research reveals differences in prescribing patterns, treatment goals, and enthusiasm for emerging therapies including Novartis’ Fabhalta and NovelMed’s ruxoprubart, as well as continued use of Alexion’s Soliris and Ultomiris and Apellis’ Empaveli. EXTON, PA, July 17, 2025 – In the latest Special Topix™: Co-Management Approaches in aHUS (US), Spherix Global
The survey shows the evolving landscape of nAMD and DME treatments, highlighting physician preferences, payer influences, and the promise of gene therapy advancements. Spherix Global Insights released data that examine the competitive and complex treatment landscape for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). The Q2 wave
More than 70% of surveyed U.S. ophthalmologists anticipate a fundamentally transformed approach to managing nAMD and DME within the next five years. Exton, PA, July 10, 2025 — Recently released research from Spherix Global Insights provides a timely look at the increasingly competitive and complex treatment landscape for neovascular age-related
New research highlights significant insurance-driven hurdles, increasing second-line uptake of Fabhalta (Novartis), and strong physician interest in pipeline therapies including zaltenibart (Omeros), pozelimab-cemdisiran (Regeneron/Alnylam), and ruxaprubart (NovelMed). EXTON, PA, July 8, 2025 – Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, chronic blood disorder that can affect individuals of any age, race, or
Systemic sclerosis and myositis interstitial lung disease subtypes flagged as most difficult to manage; specialists cite lack of effective treatments and diagnostic clarity EXTON, PA, June 17, 2025 — According to Spherix Global Insights’ newly published Special Topix™: Interstitial Lung Disease in Rheumatology (US) report, both rheumatologists and pulmonologists report
New data released from Spherix Global Insights highlights exciting opportunities in both EU and US for launch brands Hympavzi (Pfizer), Alhemo (Novo Nordisk), Qfitlia (Sanofi) and others, along with emerging gene therapies. EXTON, P.A., June 11, 2025 – As the hemophilia landscape continues to transform, new research from Spherix Global
Findings from Spherix’s fourth annual patient chart audit of more than 500 FSGS patients reveal not only a large unmet need in this market, but also optimism about the future – especially for pipeline agents coming from Travere, Novartis, Vertex, Apellis and Dimerix. EXTON, PA – June 10, 2025 –
Spherix Global Insights’ new patient audit on transfusion-dependent thalassemia reveals strong physician interest in emerging treatments like mitapivat and etavopivat, and provides insight into ideal candidates for curative gene therapies. [Exton, PA, June 04, 2025] – Despite the promise of new curative strategies for beta thalassemia, such as Casgevy (Vertex)
Despite early access friction, Bimzelx’s clinical promise and prescriber satisfaction suggest long-term opportunity in PsA and axSpA. Exton, PA., June 2, 2025 – Just over six months into its dual launch across Psoriatic Arthritis (PsA) and Axial Spondyloarthritis (axSpA), UCB’s Bimzelx (bimekizumab) is demonstrating meaningful promise, though prescriber momentum remains
Media
04.08.2024
Pfizer’s Velsipity poised to outpace BMS’ Zeposia in ulcerative colitis market, but must head off further competition: analysts
04.08.2024
As Humira biosim sales languish, Boehringer Ingelheim plots layoffs in pivot to hybrid marketing model
04.05.2024
US Gastroenterologists Project Swift Uptake of Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) for the Treatment of…
03.22.2024
Gastroenterologists Slow to Adopt Eli Lilly’s Omvoh, Pfizer’s Velsipity, and Takeda’s subcutaneous formulation of Entyvio for…
